Tango Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.95
- Today's High:
- $8.53
- Open Price:
- $8.17
- 52W Low:
- $2.47
- 52W High:
- $9.39
- Prev. Close:
- $8.25
- Volume:
- 900512
Company Statistics
- Market Cap.:
- $633.43 million
- Book Value:
- 2.407
- Revenue TTM:
- $33.70 million
- Operating Margin TTM:
- -338.4%
- Gross Profit TTM:
- $-81046000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -17.22%
- Return on Equity TTM:
- -41.76%
Company Profile
Tango Therapeutics Inc had its IPO on 2020-09-03 under the ticker symbol TNGX.
The company operates in the Healthcare sector and Biotechnology industry. Tango Therapeutics Inc has a staff strength of 110 employees.
Stock update
Shares of Tango Therapeutics Inc opened at $8.17 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.95 - $8.53, and closed at $8.1.
This is a -1.82% slip from the previous day's closing price.
A total volume of 900,512 shares were traded at the close of the day’s session.
In the last one week, shares of Tango Therapeutics Inc have increased by +13.13%.
Tango Therapeutics Inc's Key Ratios
Tango Therapeutics Inc has a market cap of $633.43 million, indicating a price to book ratio of 2.5607 and a price to sales ratio of 28.8999.
In the last 12-months Tango Therapeutics Inc’s revenue was $33.70 million with a gross profit of $-81046000 and an EBITDA of $-111852000. The EBITDA ratio measures Tango Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Tango Therapeutics Inc’s operating margin was -338.4% while its return on assets stood at -17.22% with a return of equity of -41.76%.
In Q2, Tango Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 153%.
Tango Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tango Therapeutics Inc’s profitability.
Tango Therapeutics Inc stock is trading at a EV to sales ratio of 14.3464 and a EV to EBITDA ratio of -3.4259. Its price to sales ratio in the trailing 12-months stood at 28.8999.
Tango Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $379.33 million
- Total Liabilities
- $53.63 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $664000
- Dividend Payout Ratio
- 0%
Tango Therapeutics Inc ended 2024 with $379.33 million in total assets and $0 in total liabilities. Its intangible assets were valued at $379.33 million while shareholder equity stood at $212.95 million.
Tango Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $53.63 million in other current liabilities, 88000.00 in common stock, $-318230000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $66.05 million and cash and short-term investments were $310.65 million. The company’s total short-term debt was $1,807,000 while long-term debt stood at $0.
Tango Therapeutics Inc’s total current assets stands at $320.54 million while long-term investments were $0 and short-term investments were $244.60 million. Its net receivables were $0.00 compared to accounts payable of $4.79 million and inventory worth $0.
In 2024, Tango Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $664000.
Comparatively, Tango Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $8.1
- 52-Week High
- $9.39
- 52-Week Low
- $2.47
- Analyst Target Price
- $16.83
Tango Therapeutics Inc stock is currently trading at $8.1 per share. It touched a 52-week high of $9.39 and a 52-week low of $9.39. Analysts tracking the stock have a 12-month average target price of $16.83.
Its 50-day moving average was $5.16 and 200-day moving average was $5.19 The short ratio stood at 0.66 indicating a short percent outstanding of 0%.
Around 1532.2% of the company’s stock are held by insiders while 7950% are held by institutions.
Frequently Asked Questions About Tango Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.